$5.25 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Cerus

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Stock Analysis

last close $5.25
1-mo return -6.1%
3-mo return 14.1%
avg daily vol. 1.47M
52-week high 8.06
52-week low 4.35
market cap. $986M
forward pe -
annual div. -
roe -52.8%
ltg forecast -
dividend yield -
annual rev. $183M
inst own. 82.9%

Subscribe now for daily local and international financial news